<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01045304</url>
  </required_header>
  <id_info>
    <org_study_id>TCD11418</org_study_id>
    <secondary_id>2009-016091-80</secondary_id>
    <nct_id>NCT01045304</nct_id>
  </id_info>
  <brief_title>Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer</brief_title>
  <official_title>Multicenter, Randomized, Open Label Study Evaluating a Poly(ADP-ribose) Polymerase-1(PARP-1) Inhibitor, SAR240550 (BSI-201), Administered Twice Weekly or Weekly, in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer (mTNBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

        -  To assess the objective response rate (ORR) of iniparib (SAR240550) administered as a
           60min intravenous (IV) infusion twice weekly or weekly, in combination with
           gemcitabine/carboplatin chemotherapy regimen in patients with metastatic Triple Negative
           Breast Cancer (mTNBC).

      Secondary Objectives:

        -  To assess the clinical benefit rate (CBR) defined as the rate of complete response (CR),
           partial response (PR) and stable disease (SD) lasting at least 24 weeks;

        -  To assess Progression-free survival (PFS) and the overall survival (OS);

        -  To assess the safety profile of each schedule of iniparib;

        -  To assess the biological activity in tumor tissue (substudy);

        -  To evaluate the pharmacokinetic (PK) profile of iniparib (substudy);

        -  To characterize molecular and biological profile of tumors (substudy);

        -  To assess the effect of iniparib on poly(ADP)-ribose (PAR) level in peripheral blood
           mononuclear cells (PBMC) (substudy).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study for a patient includes a period for inclusion of up to 3 weeks. The
      patients may continue treatment until disease progression, unacceptable toxicity or consent
      withdrawal, followed by a minimum of 30-day follow-up after the last study treatment
      administration.

      In case of discontinuation of study treatment, the patient will be considered as withdrawn
      from study treatment, and will be followed as planned for at least 30 days after the last
      administration of study treatment for safety purpose. In case of study treatment
      discontinuation without disease progression, efficacy data will be collected every 6 weeks
      until disease progression, death or end of study whatever comes first. After disease
      progression, the patient will be followed-up every 12 weeks (3 months) for overall survival
      until death or end of study.

      The patients who benefit from the study treatment can continue until disease progression,
      toxicity or willingness to stop.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up the cut-off date for analysis defined as 16 weeks after the 1st dose in the last participant (maximum follow-up of 14 months)</time_frame>
    <description>Proportion of participants with confirmed complete response (CR) or partial response (PR) as confirmed by an Independent Radiology Review Committee (IRRC) based on central review of scans in a blinded manner.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>Up the cut-off date for analysis defined as 16 weeks after the 1st dose in the last participant (maximum follow-up of 14 months)</time_frame>
    <description>Proportion of participants with confirmed complete response (CR) or partial response (PR) ot stable disease (SD) greater than 24 weeks as confirmed by the IRRC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up the cut-off date for analysis defined as 16 weeks after the 1st dose in the last participant (maximum follow-up of 14 months)</time_frame>
    <description>Number of days from the date of randomization to the date of disease progression (ie, radiological progression based on IRRC assessment) or the date of death (from any cause), whichever is earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up the cut-off date for analysis defined as 16 weeks after the 1st dose in the last participant (maximum follow-up of 14 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">163</enrollment>
  <condition>Breast Cancer, Metastatic</condition>
  <arm_group>
    <arm_group_label>Gencitabine + iniparib twice weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine, 1000 mg/m² IV over 30 minutes and carboplatin, area under the curve (AUC) = 2, IV over 60 minutes, both on Days 1 and 8 of 3-week cycles.
Iniparib, 5.6 mg/kg IV over 60 minutes on Days 1, 4, 8 and 11 of 3-week cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gencitabine + iniparib weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine, 1000 mg/m² IV over 30 minutes and carboplatin, area under the curve (AUC) = 2, IV over 60 minutes, both on Days 1 and 8 of 3-week cycles.
Iniparib, 11.2 mg/kg IV over 60 minutes on Days 1 and 8 of 3-week cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iniparib</intervention_name>
    <description>Pharmaceutical form: solution for infusion
Route of administration: intravenous</description>
    <arm_group_label>Gencitabine + iniparib twice weekly</arm_group_label>
    <arm_group_label>Gencitabine + iniparib weekly</arm_group_label>
    <other_name>SAR240550</other_name>
    <other_name>BSI-201</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Pharmaceutical form: solution for infusion
Route of administration: intravenous</description>
    <arm_group_label>Gencitabine + iniparib twice weekly</arm_group_label>
    <arm_group_label>Gencitabine + iniparib weekly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Pharmaceutical form: solution for infusion
Route of administration: intravenous</description>
    <arm_group_label>Gencitabine + iniparib twice weekly</arm_group_label>
    <arm_group_label>Gencitabine + iniparib weekly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Histologically documented breast cancer (either primary or metastatic site) that is ER
             (estrogen receptor)-negative, PgR (progesterone receptor)-negative ( &lt;10% tumor
             staining by immunohistochemistry [IHC]) and HER2 (human epidermal growth factor 2)
             non-overexpressing by IHC (0,1+) or, IHC 2+ and FISH (fluorescence In situ
             hybridization) negative.

          -  Metastatic breast cancer with measurable disease by the revised guideline for Response
             Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1 criteria);

          -  Prior treatment that includes:

               -  never having received anticancer therapy for metastatic disease OR

               -  having received 1 or 2 prior chemotherapy regimens in the metastatic setting
                  (prior neo-adjuvant/adjuvant systemic therapy is considered as a prior
                  chemotherapy if the first relapse occurred less than one year after the last
                  treatment administration).

        Exclusion criteria:

          -  Prior treatment with gemcitabine, carboplatin, cisplatin or any PARP inhibitor;

          -  Bone metastasis as only disease location (except for bone metastasis with measurable
             soft tissue component);

          -  Major medical conditions that might affect study participation e.g., uncontrolled
             pulmonary, renal, or hepatic dysfunction, uncontrolled infection, cardiac disease.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 036002</name>
      <address>
        <city>Parkville</city>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 036001</name>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 036003</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 056001</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 056002</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 250005</name>
      <address>
        <city>Besancon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 250003</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 250002</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 250006</name>
      <address>
        <city>Paris Cedex 05</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 250004</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 250001</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 380004</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 380001</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 380002</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 380003</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 528001</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 724002</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 724004</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 724001</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 724003</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2010</study_first_submitted>
  <study_first_submitted_qc>January 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2010</study_first_posted>
  <last_update_submitted>January 13, 2014</last_update_submitted>
  <last_update_submitted_qc>January 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Iniparib</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

